Navigation Links
Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
Date:10/27/2009

HOUSTON, Oct. 27 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

The new funding brings the total raised to date to $8.5 million, including $1.45 million from the Texas Emerging Technology Fund, $6.8 million from angel investors, and additional seed capital from founders. The $6.8 million in angel funding includes $4.3 million as Series A and $2.5 million as a Note convertible into Series A.

Bellicum Chief Executive Officer Tom Farrell stated, "It is particularly gratifying to raise sufficient funds in this challenging economic environment to advance beyond our next significant milestone, which is demonstrating clinical proof of principle for our core vaccine technology." Bellicum Founder, President & Chief Medical Officer Kevin M. Slawin, M.D., added, "Thanks to the support of our current and new investors, we are now in a strong position to realize the significant potential of our lead product to positively impact the lives of men living with prostate cancer."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to control the signaling pathways that regulate the immune response, thereby generating potent, durable antigen-specific immunity. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in clinical development for patients with advanced, androgen independent prostate cancer. The company owns or has in-licensed certain key technologies, and Chief Executive Officer Thomas J. Farrell has assembled a team of seasoned clinical, regulatory, quality and CMC consultants to advance product candidates through human clinical trials. For more information, visit www.bellicum.com.

SOURCE Bellicum Pharmaceuticals, Inc.


'/>"/>
SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Acquires Huxley Pharmaceuticals, Inc.
2. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
3. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
5. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
6. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
7. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
8. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
9. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Invetech, the ... cell and advanced therapies , has announced a ... company developing "tumor starvation" treatments for acute leukemia ... Under the agreement, Invetech will develop systems to ... Erytech,s proprietary ERYCAPS technology platform, which uses a ...
(Date:1/18/2017)... January 18, 2017 ML ... plans to publish an online presentation tomorrow, January ... sales forecast for 2017. Management reports that the ... record sales performance from its existing operations, and ... entry into the Cannabis sector through a ...
(Date:1/18/2017)... Authority Chinese Food and Drug Administration CSL ... Institute Food and Drug Administration FORT ... Glaxo Smith Klein GlaxoWellcome Global Influenza ... Immune Targeting Systems Indian Association of ... Johnson & Johnson Krka Pharmaceuticals Medicago ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... Atlanta Breast Surgery Symposium, a conference where hundreds of surgeons from over fifteen ... surgery. Covering topics from cosmetic breast augmentation to breast reconstruction for ...
(Date:1/18/2017)... ... 18, 2017 , ... From a health perspective, 2017 will clearly be the ... to chronic disease, mental health and general physical well-being. The New York Times suggested ... consider. , For one Charlottesville restaurant, good gut health is clearly on the menu. ...
(Date:1/18/2017)... ... January 18, 2017 , ... The V Foundation for Cancer Research, a ... endurance training and fundraising team, to compete in the Boston Marathon on April 17. ... finish the world’s oldest annual marathon to join Team V and support the Foundation’s ...
(Date:1/18/2017)... , ... January 18, 2017 , ... At Hallmark Nameplate, ... announce that they have achieved certification to ISO 13485. This certification is another way ... up to date products and services that they need. , The ISO 13485 Certification ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... of the revolutionary Active Brake Technology (ABT), an innovative braking system that allows ... Active Brake Technology addresses one of the biggest concerns of beginner and intermediate ...
Breaking Medicine News(10 mins):